ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Brentuximab Vedotin

Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.

Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.

Drug pageBrentuximab Vedotin: every studyAll 154 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 6, 201037 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only241 open or runningphase 3since Apr 6, 2010Feb 1, 2007none ahead
Takeda113 open or runningphase 4since Jul 1, 2013Dec 12, 2011Mar 31, 2028phase 4 · NCT06831370
Bristol-Myers Squibbits history only20 open or runningphase 3since May 1, 2017Oct 13, 2015none ahead

Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Takeda only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2011First study: phase 2 study in RecurrenceFirst studyNCT01492088 · 36 enrolled · United States, France, Germany and more
  2. Mar 27, 2012Phase 3 study in Lymphoma, Primary Cutaneous Anaplastic Large CellNCT01578499 · 131 enrolled · United States, Australia, Austria and more
  3. Oct 19, 2012Phase 3 study in Hodgkin DiseaseNCT01712490 · 1,334 enrolled · United States, Australia, Belgium and more
  4. Jul 1, 2013Phase 4 study in LymphomaNCT01909934 · 50 enrolled · Belgium, Croatia, Czechia and more
  5. Sep 23, 2013Phase 1 study in Hodgkin DiseaseNCT01950364 · 20 enrolled · Belgium, Lithuania, Spain
  6. Nov 15, 2013Phase 4 study in Hodgkin DiseaseNCT01990534 · 60 enrolled · Czechia, Germany, Malaysia and more
  7. Oct 18, 2016Phase 2 study in Hodgkin DiseaseNCT02939014 · 39 enrolled · China
  8. Nov 11, 2016Phase 2 study in Hodgkin DiseaseNCT02979522 · 59 enrolled · United States, Brazil, Italy and more
  9. Jun 30, 2022Phase 4 study in Lymphoma, T-CellNCT05442554 · 10 enrolled · China
  10. Jan 4, 2023Phase 2 study in LymphomaNCT05673785 · 52 enrolled · China
  11. Feb 14, 2025Phase 4 study in Hodgkin DiseaseNCT06831370 · 124 planned · India

Ahead

  1. Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseNCT06831370

TargetBeta

TNF →TNFRSF8 →read by rule
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule

Studies

All 11 Takeda leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06831370Hodgkin Disease · India4RecruitingMar 31, 2028124
NCT05673785Lymphoma · China2Active, not recruitingApr 27, 202552
NCT05442554Lymphoma, T-Cell · China4CompletedAug 9, 202410
NCT02979522Hodgkin Disease · United States, Brazil, Italy and more2Active, not recruitingMay 5, 202059
NCT02939014Hodgkin Disease · China2CompletedAug 2, 201839
NCT01990534Hodgkin Disease · Czechia, Germany, Malaysia and more4CompletedMar 24, 201660
NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain1CompletedOct 201420
NCT01909934Lymphoma · Belgium, Croatia, Czechia and more4CompletedMay 4, 202150
NCT01712490Hodgkin Disease · United States, Australia, Belgium and more3CompletedApr 20, 20171,334
NCT01578499Lymphoma, Primary Cutaneous Anaplastic Large Cell · United States, Australia, Austria and more3CompletedMay 31, 2016131
NCT01492088Recurrence · United States, France, Germany and more2CompletedOct 12, 201636

How it is read

Names in the registry

  • “brentuximab vedotin”, 27 entries
  • “Brentuximab vedotin”, 7 entries
  • “Brentuximab Vedotin”, 7 entries
  • “SGN-35”, 2 entries
  • “Brentuximab vedotin and rifampicin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.